A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.

Also called NCT03969719

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose basic science
Phase
Phase 2
Enrolled
  • 164 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03969719
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03969719. Randomized; double masking; primary purpose basic science. Start 2019-07-18 (actual); primary completion 2021-03-02 (actual). Results posted on 2022-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Condition
Non-alcoholic Steatohepatitis
Intervention (Drug)
Placebo
Intervention (Drug)
PF-06835919
Intervention (Drug)
PF-06835919
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct03969719
Content hash
6c481c8e01a65827b9d995ee496fae10333006d2381ef993a867d1f2f76518db